FY2024 EPS Estimates for XFOR Reduced by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for X4 Pharmaceuticals in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.67) for the year, down from their previous estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

A number of other analysts also recently issued reports on the company. HC Wainwright lowered their price target on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus lowered their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR opened at $0.57 on Thursday. The firm has a market capitalization of $97.23 million, a price-to-earnings ratio of -6.33 and a beta of 0.14. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The business has a 50 day simple moving average of $0.55 and a 200-day simple moving average of $0.62. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60.

Institutional Trading of X4 Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Verition Fund Management LLC bought a new position in X4 Pharmaceuticals in the third quarter worth approximately $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $37,000. XTX Topco Ltd bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter worth $65,000. Rhumbline Advisers increased its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the period. Finally, Jane Street Group LLC raised its holdings in shares of X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after acquiring an additional 126,296 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.